Dr. Nicholas Lydon           CML     Chronic myeloid leukemia

''Nicholas B. Lydon is a British scientist and entrepreneur. He won 2009 Lasker Clinical Award for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML). Lydon earned a BS in biochemistry from the University of Leeds, England and received his Ph.D in biochemistry from the University of Dundee, Scotland.''
Extract of http://en.wikipedia.org/wiki/Nicholas_Lydon
ARTICLES
​
" Gleevec: From Bench to Clinic"                            
November 2004, UC Santa Barbara
                                        See the history of CML
                                         Modes of access to the website
​
1 - Public access  (strongly recommended)
     On several occasions, the CML patient called CMLer will need a password  to access several modules of the website.  
                  (No registration required - Anonymous access)​
​2 - Reserved access to CMLeukemia private group
     On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
​                  (Member password required and registration required).